 Primary trial objective in this three arm trial is to assess the safety and tolerability of EMD 521873, and to determine whether the maximum tolerated dose MTD is reached with EMD 521873 doses of up to 1.5 mgkg given alone or in combination with fixed, low-dose cyclophosphamide CPA in patients with metastatic or locally advanced solid tumors or B-cell non-Hodgkin lymphoma. 